Chronic Smell and Flavor Loss Treatment Market Report 2026

The chronic smell and flavor loss treatment market size has grown strongly in recent years. It will grow from $2.64 billion in 2025 to $2.85 billion in 2026 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to increasing incidence of post-viral smell and taste disorders, growing awareness of sensory health conditions, expansion of specialty ENT clinics, rising diagnosis rates of chronic olfactory dysfunction, availability of pharmacological treatment options.

The chronic smell and flavor loss treatment market size is expected to see strong growth in the next few years. It will grow to $3.83 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to increasing research into neural regeneration therapies, rising adoption of personalized medicine approaches, expansion of home-based therapy programs, growing focus on quality-of-life improvement treatments, increasing clinical trials targeting sensory disorders. Major trends in the forecast period include increasing adoption of regenerative and stem cell-based therapies, rising use of structured olfactory training programs, growing demand for personalized sensory restoration treatments, expansion of multimodal therapeutic approaches, enhanced focus on long-term sensory rehabilitation.

The rising incidence of neurological disorders is expected to drive the growth of the chronic smell and flavor loss treatment market going forward. Neurological disorders are medical conditions that impact the brain, spinal cord, or nerves, causing symptoms such as muscle weakness, coordination difficulties, seizures, or changes in cognition and behavior. The increasing prevalence of neurological disorders is largely attributed to the aging population, as older adults are more prone to conditions such as Alzheimer’s disease, Parkinson’s disease, and stroke. Chronic smell and flavor loss treatments aid in managing neurological disorders by addressing sensory impairments, which often serve as early indicators or consequences of neurodegenerative conditions, thereby supporting timely diagnosis and enhanced patient care. For instance, in March 2023, according to the Alzheimer’s Association, a US-based nonprofit voluntary health organization, around 6.7 million Americans aged 65 and older were living with Alzheimer’s dementia in 2023, and this number is projected to rise to 13.8 million by 2060. Therefore, the increasing incidence of neurological disorders is fueling the growth of the chronic smell and flavor loss treatment market.

Major companies operating in the chronic smell and flavor loss treatment market are focusing on developing innovative therapies, such as intranasal therapeutics, to stimulate olfactory nerve regeneration and enhance smell restoration outcomes. Intranasal therapeutics are treatments administered through the nasal passages to promote olfactory nerve function, reduce inflammation, and support the recovery of smell in patients with olfactory disorders. For instance, in February 2025, Cyrano Therapeutics, Inc., a US-based clinical-stage regenerative medicine company, initiated an investigator-led clinical study to evaluate CYR-064, its patented intranasal formulation of theophylline, a broad-spectrum phosphodiesterase (PDE) inhibitor. The formulation is designed to increase olfactory neuron excitability and potentially restore the sense of smell. It features a soft-mist spray delivery system with precise droplet size and low spray velocity to optimize deposition in the olfactory region, potentially improving both therapeutic effectiveness and user convenience.

In November 2023, Fifth Sense Naturals Private Limited, a UK-based charitable organization, partnered with ENT UK to enhance care for individuals with smell and taste disorders. This collaboration aims to improve professional education, foster research, expand specialist services, and promote routine smell testing in clinical practice. ENT UK is a UK-based professional membership organization representing ear, nose, and throat (ENT) and head and neck surgeons in the United Kingdom.

Major companies operating in the chronic smell and flavor loss treatment market are Pfizer Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Viatris Inc, Hetero Labs Ltd, Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Cipla Ltd, Hikma Pharmaceuticals PLC, Lupin Limited, Zydus Lifesciences Ltd, Alkem Laboratories Ltd, Alembic Pharmaceuticals Limited, Granules India Ltd, Strides Pharma Science Limited, Tris Pharma Inc., Cyrano Therapeutics Incorporated, Teva Pharmaceutical Industries Ltd, Dr Reddys Laboratories Ltd, Mylan Pharmaceuticals Inc.

North America was the largest region in the chronic smell and flavor loss treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic smell and flavor loss treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chronic smell and flavor loss treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the chronic smell and flavor loss treatment market by increasing costs of imported pharmaceutical ingredients, nasal delivery devices, diagnostic tools, and specialized medical equipment used in sensory disorder management. Healthcare providers in North America and Europe are most affected due to reliance on imported therapeutics and devices, while Asia-Pacific faces cost pressures on pharmaceutical manufacturing inputs. These tariffs are increasing treatment costs and affecting therapy accessibility. However, they are also encouraging domestic drug manufacturing, local sourcing of medical devices, and increased investment in regional research and development for sensory disorder treatments.

The chronic smell and flavor loss treatment market research report is one of a series of new reports that provides chronic smell and flavor loss treatment market statistics, including chronic smell and flavor loss treatment industry global market size, regional shares, competitors with a chronic smell and flavor loss treatment market share, detailed chronic smell and flavor loss treatment market segments, market trends and opportunities, and any further data you may need to thrive in the chronic smell and flavor loss treatment industry. This chronic smell and flavor loss treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chronic smell and flavor loss treatment refers to the medical and therapeutic approaches used to manage long-term impairments in the senses of smell (olfaction) and taste (gustation). These treatments aim to restore sensory function, alleviate related symptoms, and improve the quality of life for individuals affected by conditions such as anosmia, hyposmia, ageusia, or dysgeusia.

The primary types of chronic smell and flavor loss treatment are smell disorder therapeutics and taste disorder therapeutics. Smell disorder therapeutics refers to treatments and interventions designed to restore, improve, or manage the sense of smell in individuals affected by olfactory dysfunctions such as anosmia, hyposmia, or parosmia. The different treatment types encompass pharmacological treatments, nutritional supplements, cognitive behavioral therapy, olfactory training, and alternative therapies. The various symptoms addressed include anosmia or hyposmia, dysgeusia, and ageusia. These treatments are administered through various routes, including oral, nasal, inhalation, and topical application, and cater to several end users, including hospitals, home care settings, and ambulatory surgical centers.

The chronic smell and flavor loss treatment market consists of revenues earned by entities by providing services such as olfactory training therapy services, pharmacological treatment services, cognitive behavioral therapy services, nutritional and dietary counseling services, and diagnostic and sensory testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic smell and flavor loss treatment market also includes sales of intranasal corticosteroid sprays, zinc gluconate, olfactory training kits, salivary stimulant tablets, and alpha-lipoic acid capsules. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.